SARS-CoV-2
R&D/ Views & Analysis/ Views and analysis
Overcoming the challenges of developing vaccines in an accelerated timeframe
mike.hammerton@pharmaphorum.com
accelerated development, assays, covid19, immunogenicity, R&D, SARS-CoV-2, vaccines
0 Comment
News/ News/ Pfizer/ Sales and Marketing
Pfizer plans considerable 2023 Comirnaty markup
Nicole Raleigh
BioNTech, Comirnaty, commercialisation, COVID-19, Moderna, Pfizer, SARS-CoV-2, The People's Vaccine Alliance, vaccines
0 Comment
News/ News/ Press Releases/ R&D
Vir awarded $1 billion multi-year BARDA influenza contract
Nicole Raleigh
BARDA, COVID-19, GSK, influenza, pandemic, prevention, respiratory disease, SARS-CoV-2, sotrovimab, Vir Biotechnology, VIR-2482
0 Comment
News/ Pfizer/ Top pharmaceutical companies
Pfizer bivalent COVID-19 vaccine starts rollout
Nicole Raleigh
bivalent vaccine, booster shot, COVID-19, flu season, NHS, Omicron, Pfizer, SARS-CoV-2
0 Comment
R&D/ Views & Analysis/ Views and analysis
COVID-19 neutralising antibody tests – an integrated approach
Catherine Longworth
antibody testing, COVID-19, immunology, SARS-CoV-2
0 Comment
Events/ Events/ Partner Content
Cell-Mediated Therapies for Infectious Disease Summit
jenna.warren@hansonwade.com
immunogenic, infectious disease, SARS-CoV-2, T-cell, vaccine
0 Comment
Cell-Mediated Therapies for Infectious Disease Summit
UK groups get £12m funding for COVID-19 monitoring software
Phil Taylor
COG-UK, coronavirus, COVID-19, genome sequencing, genomics, Sanger Institute, SARS-CoV-2, UK
0 Comment